Replimune's FDA Win Is Half a Win. The Stock Already Priced in a Loss.

Replimune's stock surged more than 120% pre-market on Thursday after the FDA approved its melanoma therapy Tudriqev, then gave most of it back as investors read between the lines. The shares closed $12.06 on Friday, down 6.2% that day and roughly 47% over five trading sessions.

The reaction makes sense if you only read the headline. It misses the math underneath.

The approval is accelerated, not full. That distinction matters. Accelerated approval lets a drug launch based on a surrogate endpoint — in Replimune's case, tumor shrinkage rates — but it requires a confirmatory Phase 3 trial (IGNYTE-3) to prove actual patient benefit. If the trial fails, the FDA can pull Tudriqev off the market. The approval clock starts ticking now, and the confirmatory timeline is the only thing standing between a product launch and a withdrawal notice.

FDA reviewers made that tension explicit. Internal review documents show concerns that the tumor shrinkage Replimune measured in its trials may reflect a local procedure effect — the physical injection damaging the lesion — rather than genuine systemic antitumor activity. The agency also flagged that the RECIST v1.1 measurement standard (the oncology industry's benchmark for tracking tumor size) may inflate both the objective response rate and duration of response when applied to injected lesions. Those are not minor footnotes. They are the core scientific question that the confirmatory trial must answer.

Three things explain the selloff. Only one is structural.

The first is the accelerated-approval condition itself. The market priced Tudriqev as a commercial product Thursday morning and repriced it as a conditional experiment by Thursday afternoon. That repricing is real — the confirmatory trial is a binary risk — but the market has already sold the stock as if the trial is more likely to fail than succeed. There's no data to support that asymmetry.

The second is cash. Replimune held $209 million in cash as of its latest balance sheet, against $284.6 million in trailing-twelve-month free cash flow burn. The company told investors its resources fund operations into the first quarter of 2027. That runway was stated before the approval and before any commercial revenue begins. Tudriqev generates zero revenue today. The burn rate may accelerate once the company scales manufacturing and builds a commercial team for launch. That is a real pressure point. But $209 million of cash on an $828 million enterprise value gives the company an option, not an emergency — and Tudriqev's combination with Bristol-Myers Squibb's Opdivo (nivolumab) means BMS has commercial infrastructure that could reduce Replimune's go-to-market costs if partnership terms include co-promotion or revenue sharing.

The third is competitive precedent. Amgen's Imlygic (T-VEC), the original oncolytic virus approved for melanoma in 2015, was a commercial also-ran. The treatment is injected directly into accessible tumors — a niche use case that limited adoption and never generated blockbuster revenue. Tudriqev faces the same administration challenge. But Tudriqev is given alongside a checkpoint inhibitor (Opdivo), which changes the clinical context: it's no longer a standalone injection into visible tumors but part of a combination regimen for patients who've failed first-line immunotherapy. The patient population and the treatment paradigm are different, even if the delivery mechanism is familiar.

The forward math vs. the panic narrative.

At a $1.013 billion market cap and $828 million enterprise value, Replimune trades as if Tudriqev is a clinical-stage asset that hasn't earned approval. It just did. The question isn't whether the drug works on a surrogate endpoint — the FDA accepted that data to grant accelerated approval. The question is whether the confirmatory trial confirms real-world benefit and whether Replimune can fund the gap between launch and confirmation.

AInvest's aggregate signal labels the stock a Buy, with a composite analysis rating of 1.67 and a liquidity rating of 7.94 — but opaque scores don't close the argument. The forward multiple does.

Replimune has no revenue, no earnings, and a negative P/E that means traditional valuation ratios don't apply. So the valuation question reduces to enterprise value versus the addressable opportunity. The global oncolytic virus therapy market was $3.71 billion in 2025 and is projected to grow at a 12.7% CAGR through 2035. Tudriqev targets the advanced melanoma population after anti-PD-1 failure — a defined, underserved patient group where the FDA acknowledged significant unmet need. Even a modest share of that market would represent a company worth well north of $828 million.

The key risk is the confirmatory trial. If IGNYTE-3 underperforms, the approval evaporates and the $209 million in cash gets consumed proving a negative. That is the break condition that would make the thesis wrong. Until that trial runs and reports, the market is pricing in a failure that hasn't happened yet.

What to watch.

The IGNYTE-3 timeline and design. The cash run rate post-approval — whether commercial build-out accelerates the burn beyond the Q1 2027 runway. Any partnership details with Bristol-Myers Squibb around Tudriqev distribution and revenue. The advisory committee voted 10-3 in favor of approval in late July; that margin of support suggests the scientific community sees merit even if the FDA's internal reviewers were skeptical.

The stock may need to find a bottom before the forward math becomes obvious to the broader market. But at less than $830 million in enterprise value for an FDA-approved therapy with a confirmed combination partner and a runway into next year, Replimune doesn't price in the scenario where Tudriqev becomes a working product rather than a conditional experiment.